Cargando…
Sepsis at ICU admission does not decrease 30-day survival in very old patients: a post-hoc analysis of the VIP1 multinational cohort study
BACKGROUND: The number of intensive care patients aged ≥ 80 years (Very old Intensive Care Patients; VIPs) is growing. VIPs have high mortality and morbidity and the benefits of ICU admission are frequently questioned. Sepsis incidence has risen in recent years and identification of outcomes is of c...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221097/ https://www.ncbi.nlm.nih.gov/pubmed/32406016 http://dx.doi.org/10.1186/s13613-020-00672-w |
_version_ | 1783533298030477312 |
---|---|
author | Ibarz, Mercedes Boumendil, Ariane Haas, Lenneke E. M. Irazabal, Marian Flaatten, Hans de Lange, Dylan W. Morandi, Alessandro Andersen, Finn H. Bertolini, Guido Cecconi, Maurizio Christensen, Steffen Faraldi, Loredana Fjølner, Jesper Jung, Christian Marsh, Brian Moreno, Rui Oeyen, Sandra Öhman, Christina Agwald Bollen Pinto, Bernardo Soliman, Ivo W. Szczeklik, Wojciech Valentin, Andreas Watson, Ximena Zaferidis, Tilemachos Guidet, Bertrand Artigas, Antonio |
author_facet | Ibarz, Mercedes Boumendil, Ariane Haas, Lenneke E. M. Irazabal, Marian Flaatten, Hans de Lange, Dylan W. Morandi, Alessandro Andersen, Finn H. Bertolini, Guido Cecconi, Maurizio Christensen, Steffen Faraldi, Loredana Fjølner, Jesper Jung, Christian Marsh, Brian Moreno, Rui Oeyen, Sandra Öhman, Christina Agwald Bollen Pinto, Bernardo Soliman, Ivo W. Szczeklik, Wojciech Valentin, Andreas Watson, Ximena Zaferidis, Tilemachos Guidet, Bertrand Artigas, Antonio |
author_sort | Ibarz, Mercedes |
collection | PubMed |
description | BACKGROUND: The number of intensive care patients aged ≥ 80 years (Very old Intensive Care Patients; VIPs) is growing. VIPs have high mortality and morbidity and the benefits of ICU admission are frequently questioned. Sepsis incidence has risen in recent years and identification of outcomes is of considerable public importance. We aimed to determine whether VIPs admitted for sepsis had different outcomes than those admitted for other acute reasons and identify potential prognostic factors for 30-day survival. RESULTS: This prospective study included VIPs with Sequential Organ Failure Assessment (SOFA) scores ≥ 2 acutely admitted to 307 ICUs in 21 European countries. Of 3869 acutely admitted VIPs, 493 (12.7%) [53.8% male, median age 83 (81–86) years] were admitted for sepsis. Sepsis was defined according to clinical criteria; suspected or demonstrated focus of infection and SOFA score ≥ 2 points. Compared to VIPs admitted for other acute reasons, VIPs admitted for sepsis were younger, had a higher SOFA score (9 vs. 7, p < 0.0001), required more vasoactive drugs [82.2% vs. 55.1%, p < 0.0001] and renal replacement therapies [17.4% vs. 9.9%; p < 0.0001], and had more life-sustaining treatment limitations [37.3% vs. 32.1%; p = 0.02]. Frailty was similar in both groups. Unadjusted 30-day survival was not significantly different between the two groups. After adjustment for age, gender, frailty, and SOFA score, sepsis had no impact on 30-day survival [HR 0.99 (95% CI 0.86–1.15), p = 0.917]. Inverse-probability weight (IPW)-adjusted survival curves for the first 30 days after ICU admission were similar for acute septic and non-septic patients [HR: 1.00 (95% CI 0.87–1.17), p = 0.95]. A matched-pair analysis in which patients with sepsis were matched with two control patients of the same gender with the same age, SOFA score, and level of frailty was also performed. A Cox proportional hazard regression model stratified on the matched pairs showed that 30-day survival was similar in both groups [57.2% (95% CI 52.7–60.7) vs. 57.1% (95% CI 53.7–60.1), p = 0.85]. CONCLUSIONS: After adjusting for organ dysfunction, sepsis at admission was not independently associated with decreased 30-day survival in this multinational study of 3869 VIPs. Age, frailty, and SOFA score were independently associated with survival. |
format | Online Article Text |
id | pubmed-7221097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-72210972020-05-15 Sepsis at ICU admission does not decrease 30-day survival in very old patients: a post-hoc analysis of the VIP1 multinational cohort study Ibarz, Mercedes Boumendil, Ariane Haas, Lenneke E. M. Irazabal, Marian Flaatten, Hans de Lange, Dylan W. Morandi, Alessandro Andersen, Finn H. Bertolini, Guido Cecconi, Maurizio Christensen, Steffen Faraldi, Loredana Fjølner, Jesper Jung, Christian Marsh, Brian Moreno, Rui Oeyen, Sandra Öhman, Christina Agwald Bollen Pinto, Bernardo Soliman, Ivo W. Szczeklik, Wojciech Valentin, Andreas Watson, Ximena Zaferidis, Tilemachos Guidet, Bertrand Artigas, Antonio Ann Intensive Care Research BACKGROUND: The number of intensive care patients aged ≥ 80 years (Very old Intensive Care Patients; VIPs) is growing. VIPs have high mortality and morbidity and the benefits of ICU admission are frequently questioned. Sepsis incidence has risen in recent years and identification of outcomes is of considerable public importance. We aimed to determine whether VIPs admitted for sepsis had different outcomes than those admitted for other acute reasons and identify potential prognostic factors for 30-day survival. RESULTS: This prospective study included VIPs with Sequential Organ Failure Assessment (SOFA) scores ≥ 2 acutely admitted to 307 ICUs in 21 European countries. Of 3869 acutely admitted VIPs, 493 (12.7%) [53.8% male, median age 83 (81–86) years] were admitted for sepsis. Sepsis was defined according to clinical criteria; suspected or demonstrated focus of infection and SOFA score ≥ 2 points. Compared to VIPs admitted for other acute reasons, VIPs admitted for sepsis were younger, had a higher SOFA score (9 vs. 7, p < 0.0001), required more vasoactive drugs [82.2% vs. 55.1%, p < 0.0001] and renal replacement therapies [17.4% vs. 9.9%; p < 0.0001], and had more life-sustaining treatment limitations [37.3% vs. 32.1%; p = 0.02]. Frailty was similar in both groups. Unadjusted 30-day survival was not significantly different between the two groups. After adjustment for age, gender, frailty, and SOFA score, sepsis had no impact on 30-day survival [HR 0.99 (95% CI 0.86–1.15), p = 0.917]. Inverse-probability weight (IPW)-adjusted survival curves for the first 30 days after ICU admission were similar for acute septic and non-septic patients [HR: 1.00 (95% CI 0.87–1.17), p = 0.95]. A matched-pair analysis in which patients with sepsis were matched with two control patients of the same gender with the same age, SOFA score, and level of frailty was also performed. A Cox proportional hazard regression model stratified on the matched pairs showed that 30-day survival was similar in both groups [57.2% (95% CI 52.7–60.7) vs. 57.1% (95% CI 53.7–60.1), p = 0.85]. CONCLUSIONS: After adjusting for organ dysfunction, sepsis at admission was not independently associated with decreased 30-day survival in this multinational study of 3869 VIPs. Age, frailty, and SOFA score were independently associated with survival. Springer International Publishing 2020-05-13 /pmc/articles/PMC7221097/ /pubmed/32406016 http://dx.doi.org/10.1186/s13613-020-00672-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Ibarz, Mercedes Boumendil, Ariane Haas, Lenneke E. M. Irazabal, Marian Flaatten, Hans de Lange, Dylan W. Morandi, Alessandro Andersen, Finn H. Bertolini, Guido Cecconi, Maurizio Christensen, Steffen Faraldi, Loredana Fjølner, Jesper Jung, Christian Marsh, Brian Moreno, Rui Oeyen, Sandra Öhman, Christina Agwald Bollen Pinto, Bernardo Soliman, Ivo W. Szczeklik, Wojciech Valentin, Andreas Watson, Ximena Zaferidis, Tilemachos Guidet, Bertrand Artigas, Antonio Sepsis at ICU admission does not decrease 30-day survival in very old patients: a post-hoc analysis of the VIP1 multinational cohort study |
title | Sepsis at ICU admission does not decrease 30-day survival in very old patients: a post-hoc analysis of the VIP1 multinational cohort study |
title_full | Sepsis at ICU admission does not decrease 30-day survival in very old patients: a post-hoc analysis of the VIP1 multinational cohort study |
title_fullStr | Sepsis at ICU admission does not decrease 30-day survival in very old patients: a post-hoc analysis of the VIP1 multinational cohort study |
title_full_unstemmed | Sepsis at ICU admission does not decrease 30-day survival in very old patients: a post-hoc analysis of the VIP1 multinational cohort study |
title_short | Sepsis at ICU admission does not decrease 30-day survival in very old patients: a post-hoc analysis of the VIP1 multinational cohort study |
title_sort | sepsis at icu admission does not decrease 30-day survival in very old patients: a post-hoc analysis of the vip1 multinational cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221097/ https://www.ncbi.nlm.nih.gov/pubmed/32406016 http://dx.doi.org/10.1186/s13613-020-00672-w |
work_keys_str_mv | AT ibarzmercedes sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT boumendilariane sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT haaslennekeem sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT irazabalmarian sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT flaattenhans sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT delangedylanw sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT morandialessandro sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT andersenfinnh sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT bertoliniguido sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT cecconimaurizio sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT christensensteffen sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT faraldiloredana sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT fjølnerjesper sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT jungchristian sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT marshbrian sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT morenorui sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT oeyensandra sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT ohmanchristinaagwald sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT bollenpintobernardo sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT solimanivow sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT szczeklikwojciech sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT valentinandreas sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT watsonximena sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT zaferidistilemachos sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT guidetbertrand sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT artigasantonio sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy AT sepsisaticuadmissiondoesnotdecrease30daysurvivalinveryoldpatientsaposthocanalysisofthevip1multinationalcohortstudy |